Survival analyses of postoperative lung cancer patients: an investigation using Japanese administrative data

SpringerPlus

Table 1 Clinical stage–specific survival rates (1 year to 5 years) of postoperative non-small cell lung cancer patients

		Survival rates (%) and number of subjects at risk
	N	1Y			2Y			3Y			4Y			5Y
Clinical stages (DPC data)		%	95% CI	n^a	%	95% CI	n	%	95% CI	n	%	95% CI	n	%	95% CI
IA	3812	98.2	(±0.6)	2014	96.3	(±0.8)	939	92.6	(±1.8)	318	89.3	(±3.1)	36	85.8	(±7.3)
IB	1581	95.4	(±1.2)	781	90.7	(±2.2)	365	86.6	(±2.9)	137	85.0	(±3.7)	25	85.0	(±3.7)
IIA	420	94.6	(±2.5)	200	87.8	(±4.7)	84	78.0	(±8.0)	21	73.9	(±11.0)	4	24.6	(±39.6)
IIB	480	86.4	(±3.7)	230	71.7	(±5.9)	92	66.3	(±7.6)	34	58.6	(±10.6)	7	58.6	(±10.6)
IIIA	771	89.1	(±2.5)	386	78.7	(±4.1)	146	71.1	(±6.1)	58	59.3	(±11.6)	12	44.5	(±26.7)
JJCLCR (2011) Clinical stages 6th edition^b
IA	6295	97.0			92.7			89.1			85.5			82.0
IB	2788	91.0			81.9			74.8			68.0			63.4
IIA	203	89.7			75.0			64.3			59.2			55.4
IIB	899	83.7			69.5			59.8			54.0			48.6
IIIA	940	80.9			64.3			53.6			47.7			43.3
JJCLCR (2011) Clinical stages 7th edition^b
IA	6295	97.0			92.7			89.1			85.5			82.0
IB	2339	92.5			84.4			77.6			70.8			66.1
IIA	819	88.7			85.4			66.8			60.2			54.5
IIB	648	80.0			63.6			54.7			50.4			46.4
IIIA	1216	81.4			64.7			53.7			47.3			42.8
IASLC (2009) Clinical stages 6th edition^c
IA	831													50
IB	1842													40
IIA	25													24
IIB	2151													25
IIIA	3005													18
IASLC (2009) Clinical stages 7th edition^c
IA	831													50
IB	1284													43
IIA	483													36
IIB	2248													25
IIIA	3175													19

^aNumber at risk.
^bData from the Japanese Joint Committee for Lung Cancer Registration (JJCLCR) in 2011 (Sawabata et al. 2011); 95% CI were not available for these data.
^cData from the International Association for the Study of Lung Cancer (IASLC) in 2009 (Tanoue and Detterbeck 2009); 95% CI were not available for these data.